What urologists can expect in Q2 of 2026

The first quarter of 2026 delivered a steady stream of regulatory milestones and practice-shaping data for urologists. Notable highlights included the FDA’s approval of an accelerated thawing method for nadofaragene firadenovec-vncg (Adstiladrin), as well as 510(k) clearances for the Urocross Expander System for benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) and the Break Wave Lithotripsy device for kidney stones, reflecting continued innovation across both oncology and benign conditions. These developments were complemented by data presented at major forums such as the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and the European Association of Urology Congress, where emerging evidence helped refine treatment paradigms across genitourinary malignancies.